National Jewish Health is designated by the State of Colorado to administer the medication bamlanivimab to qualified patients diagnosed with COVID-19. The Infusion Center for COVID-19 Care is a designated COVID-19 patient care area dedicated to the delivery of bamlanivimab infusions.
Patients must be referred to by a physician and have been selected by the state lottery process to receive this medication treatment in the National Jewish Health Infusion Center for COVID-19.
After qualifying through the state of Colorado through a lottery system and being referred to National Jewish Health, patients will be scheduled for a four-hour appointment on our main campus in Denver.
Bamlanivimab is treatment of mild to moderate coronavirus disease 2019 (COVID19) in adults and pediatric patients who are at high risk for progressing to severe COVID-19 and/or hospitalization. It is an investigational medicine used for the treatment of COVID-19 in non-hospitalized adults and adolescents 12 years of age and older with mild to moderate symptoms who weigh 88 pounds (40 kg) or more, and who are at high risk for developing severe COVID-19 symptoms or the need for hospitalization.
Bamlanivimab is investigational because it is still being studied. There is limited information known about the safety or effectiveness of using bamlanivimab to treat people with COVID-19. The FDA has authorized the emergency use of bamlanivimab for the treatment of COVID-19 under an Emergency Use Authorization (EUA).
For more information, view the FDA Fact Sheet for Patients, Parents and Caregivers Emergency Use Authorization (EUA) of Bamlanivimab for Coronavirus Disease 2019 (COVID-19).
The information on our website is medically reviewed and accurate at the time of publication. Due to the changing nature of the COVID-19 pandemic, information may have since changed. CDC.gov and your state’s health department may offer additional guidance.